Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

KidneyGenRx Developing RNA-editing based therapy for renal cystic ciliopathies

Coordinator
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center, Israel
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101212591

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic Kidney Disease (CKD) is a significant global health burden, affecting approximately 10% of the adult population worldwide. It is estimated that 10-20% of advanced CKD cases are caused by genetic kidney diseases, with renal cystic ciliopathies being the most common genetic contributors. In the Israeli Druze population, we have identified a novel homozygous mutation in the WDR19 gene as the leading cause of end-stage kidney disease (ESKD), particularly leading to renal failure in young adults.

Currently, kidney failure caused by renal cystic ciliopathies can only be treated through renal replacement therapies, such as dialysis or transplantation, as no specific therapeutic interventions are available. This project aims to establish proof of concept that RNA editing can serve as a viable therapeutic strategy for genetically driven kidney failure. By employing Site-Directed RNA Editing (SDRE) through the action of Adenosine Deaminase Acting on RNA (ADAR) enzymes, we aim to correct the pathogenic WDR19 mutation (c.878G>A) at the RNA level.

Our efforts will focus on optimizing guide RNA (gRNA) design and improving delivery mechanisms to maximize editing efficiency and therapeutic outcomes. The efficacy of this approach will be evaluated by its ability to rescue the disease phenotype in patient-derived induced pluripotent stem cell (iPSC)-derived kidney organoids and further validated in murine models. If successful, this proof-of-concept project could pave the way for RNA editing-based therapies as a transformative treatment for genetic kidney diseases.

Topics

Who is involved

OrganisationCityCountryRole
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical CenterRamat GanIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI